UNSPSC 51273800: Combination analgesics

This classification denotes combination drugs that consist of various combined compounds capable of relieving pain without the loss of consciousness. Typical combination analgesic constituents are antipyrine, benzocaine, and methyl salicylate.

UNSPSC 51273800 Combination analgesics, a Class code, spans the procurement of pharmaceutical products and related health-supply systems by state and local public bodies, though recent state and local opportunities tagged to this code show significant scope divergence. Seminole County, Florida recently sought naloxone and safe drug deactivation systems through competitive bidding, while the Texas Health and Human Services Commission and the Minnesota Multistate Cooperative Purchasing Alliance have pursued broader pharmaceutical supply arrangements — direct-to-manufacturer prescriptions and generic multi-source pharmaceuticals with over-the-counter products respectively. The issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances serving participating government jurisdictions. The procurement reflects a mix of immediate supply needs (naloxone for community health programs), market-intelligence gathering (Texas HHS exploration of direct-manufacturer relationships), and framework contracting for ongoing pharmaceutical distribution to state and local facilities.

Recent activity spans Florida, Texas, and Minnesota. Seminole County's IFB60459723LAS, posted June 30, 2026, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida and a response deadline of July 26, 2026 (note: the source lists an inconsistent prior date of July 26, 2023); the contract runs two years with a one-year renewal option and includes potential FEMA funding with associated federal compliance requirements. The Texas Health and Human Services Commission issued RFI HHS0017013 on March 27, 2026 (response deadline April 3, 2026) to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration's Office of State Procurement, administering the MMCAP cooperative, issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026; awarded vendors must work through three authorized wholesalers and participate in framework agreements effective July 1, 2026, serving Minnesota, Oregon, and other participating jurisdictions. Vendors pursuing these opportunities must manage regulatory compliance (cGMP, DSCSA, FDA requirements), maintain specified insurance coverage, and accept administrative fees and performance penalty structures tied to contract administration and fulfillment timelines.